Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002042 · ClinicalTrials.gov registry record · NA
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia
A NA study of HIV Infections and Cytopenias, sponsored by Ortho Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
- 1
- Study location
NCT00002042 is a NA study of HIV Infections and Cytopenias that has completed, run by Ortho Pharmaceuticals. The trial reports 1 study location across 1 state.
The verdict
NCT00002042, a NA study of HIV Infections and Cytopenias, has completed, sponsored by Ortho Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 1
- Study location
Study Summary
To determine the safety and efficacy of r-HuEPO administration to patients with AIDS or advanced AIDS related complex (ARC) and anemia secondary to their disease.
Conditions Studied
Interventions
- DRUG Epoetin alfa
Study Locations (1)
New Jersey
- Ortho Pharmaceutical Corp - Raritan
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002042
The ClinicalTrials.gov registry entry for NCT00002042 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Ortho Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Epoetin alfa is the first listed.
NCT00002042 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00002042 about?
NCT00002042 is a clinical study titled "A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia". To determine the safety and efficacy of r-HuEPO administration to patients with AIDS or advanced AIDS related complex (ARC) and anemia secondary to their disease.
What is the current status of trial NCT00002042?
This trial is currently completed. It is a NA study.
What conditions does trial NCT00002042 study?
This clinical trial studies the following conditions: HIV Infections, Cytopenias.
What interventions are being tested in trial NCT00002042?
The interventions under investigation include: Epoetin alfa (DRUG).
Who is sponsoring clinical trial NCT00002042?
This trial is sponsored by Ortho Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002042 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.